Evidence map›Paper›PMID 29603776›Full record

ArticleNeurourology and urodynamics2018

Selective bladder denervation for overactive bladder (OAB) syndrome: From concept to healing outcomes using the ovine model.

James Fugett, Lynette Phillips, Emily Tobin, Eric Whitbrook, Haydon Bennett, Joshua Shrout, James E Coad

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Neurourology and urodynamics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06796855 (Selective Bladder Denervation vs Intramuscular Onabotulinum Toxin A for Refractory Overactive Bladder), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06796855 phase4completednot on this mapstarted 2023, after this paper: background citation

Selective Bladder Denervation vs Intramuscular Onabotulinum Toxin A for Refractory Overactive Bladder: A Randomized Comparative Study

TypeinterventionalSponsorBagcilar Training and Research HospitalRan2023 to 2024Enrolled60ConditionsOveractive Bladder Syndrome, Refractory Overactive BladderArmsSelective Bladder Denervation via Radiofrequency Ablation, Intravesical Onabotulinum Toxin A Injection
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Validation of an ovine vesicovaginal fistula model.International urogynecology journal · 2022
    Article
  4. Review
  5. Article
  6. Electroacupuncture Alleviates Bladder Overactivity via Inhabiting Bladder P2XEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

James FugettPathology Laboratory for Translational Medicine, West Virginia University School of Medicine, Morgantown, West Virginia.
Lynette PhillipsAmerican Preclinical Services, Minneapolis, Minnesota.
Emily TobinAmerican Preclinical Services, Minneapolis, Minnesota.
Eric WhitbrookAmphora Medical, Inc., Maple Grove, Minnesota.
Haydon BennettPathology Laboratory for Translational Medicine, West Virginia University School of Medicine, Morgantown, West Virginia.
Joshua ShroutPathology Laboratory for Translational Medicine, West Virginia University School of Medicine, Morgantown, West Virginia.
James E CoadPathology Laboratory for Translational Medicine, West Virginia University School of Medicine, Morgantown, West Virginia.ORCID 0000-0002-7913-2561
West Virginia University · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
Amphora Medical, Inc.NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

aimsWe evaluated a Selective Bladder Denervation (SBD) device, which uses radiofrequency ablation, for the treatment of overactive bladder syndrome in terms of its nerve denervation, ablation characteristics, and post-treatment healing.

methodsUsing the SBD device, eight fresh extirpated ovine bladder trigones were treated (90°C set point for 60 s) and nitroblue tetrazolium viability stained to characterize the ablation. In addition, 12 trigones were treated in vivo with three adjacent ablations and divided into survival cohorts: Day 7, Day 30, and Day 90 to assess the ablations and their associated healing.

resultsThe ex vivo single trigone ablations had a 7.9 ± 0.9 mm width and 5.7 ± 1.0 mm thickness that involved the submucosa, detrusor muscle, adventitia, and vagina. Microscopic viability staining confirmed complete nerve necrosis within the targeted tissue. The in vivo Day 7 trigones supported the ex vivo ablation characteristics and showed up to minimal inflammation, granulation tissue, and collagen fibrosis. Day 30 trigones had essentially absent inflammation and granulation tissue with evolving collagen fibrosis at the ablation's periphery. Day 90 trigones had essentially absent acute inflammation, minimal chronic inflammation, essentially absent granulation tissue, and up to mild collagen fibrosis. No ureteral/urethral alterations, vesico-vaginal fistulas, or other complications were identified.

conclusionsThe SBD device provided a targeted trigone ablation with resultant denervation. The tissue healing timeline followed that expected for a hyperthermic ablation and was characterized by a fibroproliferative healing response with limited inflammation and granulation tissue. The ablations did not impact the overlying bladder mucosal surface.

Indexed as

AnimalsCollagenDenervationFemaleFibrosisGranulation TissueNecrosisSheepSubmucous PlexusTreatment OutcomeUrinary BladderUrinary Bladder, OveractiveUrologic Surgical ProceduresVaginaCollagendenervationoveractive bladdertissue ablationtissue healing

Identifiers

PMID29603776
PMCPMC6321764
OpenAlexW2794944261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.